United States Copper Index Fund vs Heron Therapeutics Inc — how do they compare? United States Copper Index Fund trades at $40.1 (market cap $708.28M), while Heron Therapeutics Inc trades at $0.37 (market cap $68.01M). The key difference: United States Copper Index Fund is far larger — about 10.4× Heron Therapeutics Inc's market cap, and United States Copper Index Fund is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold United States Copper Index Fund for 48 Days and Heron Therapeutics Inc for 35 Days on average.
| CPER | HRTX | |
|---|---|---|
Market Cap | $708.28M | $68.01M |
Volume | 339,046 | 1,891,941 |
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $41.43 | $1.49 |
52-Week Low | $30.27 | $0.27 |
Typical Hold Time | 48 Days | 35 Days |
Enterprise Value | — | $174.75M |
Signals from Pluang's Aura AI — not financial advice
CPER is trading at $39.81, down 0.55% on the day, with a neutral technical signal overall. The stock shows bullish momentum in moving averages but neutral oscillators, with key support at $39 and resistance at $40. Recent news highlights strong copper demand driven by AI infrastructure needs, though copper prices have shown volatility with recent declines.
The outlook for CPER is mixed, with positive copper demand fundamentals balanced by near-term price volatility. Investment opportunities center on exposure to copper's role in AI and electrification trends, while risks include commodity price swings and potential supply chain disruptions. Wall Street sentiment appears cautiously optimistic given copper's strategic importance.
Heron Therapeutics (HRTX) is trading at $0.39, up 17.58% today, with a bullish technical outlook from moving averages but mixed signals from oscillators. The company maintains strong gross margins of 70.07% but continues to report net losses, with Q2 2026 missing both EPS and revenue expectations. Analyst sentiment remains overwhelmingly positive with 89% buy ratings despite recent earnings disappointments and negative profitability metrics.
While analyst consensus is strongly bullish, HRTX faces significant fundamental challenges including consistent net losses, negative ROE of -78.72%, and cash flow concerns. The stock's current momentum appears driven by technical factors rather than improving fundamentals, creating a high-risk investment profile that requires careful monitoring of upcoming Q3 earnings and revenue stabilization efforts.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
CPER is a commodity ETF that tracks the price of copper futures via the SummerHaven Copper Index. It provides direct exposure to the 'red metal' using a rules-based strategy to select futures contracts, making it a key tool for hedging or betting on industrial growth and electrification.
Read more on CPER →Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →